Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Bill to make collaborative drug-therapy agreements confidential divides providers and media advocates
Summary
House Bill 2,176 would exempt collaborative drug therapy agreements (CDTAs) from public disclosure except when the agreement is the basis for disciplinary action; supporters say confidentiality protects providers (including those prescribing medication abortion or gender-affirming care), while journalists and open-government groups warn about reduced transparency of clinical arrangements.
OPR staff summarized House Bill 2,176 as a narrowly targeted change: CDTAs (agreements setting a pharmacist's prescriptive authority under supervision or protocols) would be confidential under the Public Records Act except where the CDTA forms the basis of an order, stipulation or disciplinary action. Disclosed CDTAs in disciplinary cases must have personal information redacted for persons who are not the subject of the disciplinary action.
Representative Mylene Tai (41st District), the bill sponsor, said CDTAs are longstanding clinical tools that increase access to care and argued confidentiality is…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
